Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials
Ann Rheum Dis 2022;81:962–969 doi: 10.1136/annrheumdis-2021-221847
Bruce, et al. investigate the degree of concordance between BICLA and SRI-4 response across anifrolumab trials (TULIP-1, TULIP-2 and MUSE) in order to better understand drivers of discrepant systemic lupus erythematosus (SLE) trial results.
Their results showed that, across the trials, most patients had concordant BICLA/SRI-4 outcomes, and dual BICLA/SRI-4 responses favoured anifrolumab. However, careful attention to baseline disease activity and monitoring glucocorticoid taper variation will be essential in future SLE trials.